Published in JAMA on October 20, 2004
Abnormal angiogenesis in diabetes mellitus. Med Res Rev (2003) 2.41
Carotid plaque pathology: thrombosis, ulceration, and stroke pathogenesis. Stroke (2005) 2.00
Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation (2005) 1.97
IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J Biol Chem (2004) 1.65
The cardiovascular effects of erythropoietin. Cardiovasc Res (2003) 1.59
Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost (2002) 1.58
Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res (2003) 1.52
The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats. J Biol Chem (2004) 1.31
Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovasc Res (2002) 1.30
Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol (2004) 1.23
Association between symptoms reported in a population questionnaire and future ischemic stroke: the ARIC study. Neuroepidemiology (2004) 1.15
Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system. J Biol Chem (2005) 1.12
Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis (2011) 1.12
Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. Blood Coagul Fibrinolysis (2003) 1.12
Angiotensin II type 1 receptor blockade prevents alcoholic cardiomyopathy. Circulation (2006) 1.10
Surgery for carotid artery stenosis. BMJ (2004) 1.06
Mast cell tryptase: a new biomarker in patients with stable coronary artery disease. Atherosclerosis (2005) 1.05
Regulator of G protein signaling 5 marks peripheral arterial smooth muscle cells and is downregulated in atherosclerotic plaque. J Vasc Surg (2004) 1.00
Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries. Chem Biol (2008) 0.96
Relation of anemia to diastolic heart failure and the effect on outcome. Am J Cardiol (2004) 0.96
Vascular origin of a soluble truncated form of the hepatocyte growth factor receptor (c-met). Circ Res (2002) 0.96
ABO blood types: influence on infarct size, procedural characteristics and prognosis. Thromb Res (2008) 0.95
Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med (2004) 0.95
Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review. Eur J Haematol (2008) 0.94
Beyond the platelet count: heparin antibodies as independent risk predictors. Am Heart J (2007) 0.94
Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation (2003) 0.93
Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary intervention. Am Heart J (2007) 0.92
Aging and thrombosis. Semin Thromb Hemost (2002) 0.92
Intrabody and intrakine strategies for molecular therapy. Mol Ther (2003) 0.91
Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system. Thromb Res (2002) 0.91
Association of diabetes, homocysteine, and HDL with cognition and disability after stroke. Neurology (2007) 0.91
Comparison of retinal vasodilator and constrictor responses in type 2 diabetes. Acta Ophthalmol (2012) 0.89
Changes in plasma homocyst(e)ine in the acute phase after stroke. Stroke (2002) 0.89
Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. Blood (2002) 0.88
Transglutaminases: the missing link in nephrogenic systemic fibrosis. Am J Dermatopathol (2007) 0.87
Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction. Am Heart J (2009) 0.86
Impaired retinal vasodilator responses in prediabetes and type 2 diabetes. Acta Ophthalmol (2013) 0.86
Biomarkers for stroke: in search of fingerprints. J Stroke Cerebrovasc Dis (2011) 0.86
Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts. J Thromb Thrombolysis (2006) 0.85
Final results of the ReoPro readministration registry. Am J Cardiol (2004) 0.85
Assessment of pre- and post-methionine load homocysteine for prediction of recurrent stroke and coronary artery disease in the Vitamin Intervention for Stroke Prevention Trial. Atherosclerosis (2007) 0.85
Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. Am Heart J (2006) 0.84
Reduced inhibition by abciximab in platelets with the PlA2 polymorphism. Am Heart J (2002) 0.84
Cytoprotective effect of recombinant human erythropoietin produced in transgenic tobacco plants. PLoS One (2013) 0.84
Routine hematologic clinical tests as prognostic markers in patients with acute coronary syndromes. Am Heart J (2008) 0.84
Low plasma levels of FGF-2 and PDGF-BB are associated with cardiovascular events in type II diabetes mellitus (diabetes heart study). Dis Markers (2007) 0.84
N-Glycosylation engineering of tobacco plants to produce asialoerythropoietin. Plant Cell Rep (2012) 0.84
Plasma total homocysteine levels in stroke patients screened for the vitamin intervention for stroke prevention clinical trial in the era of folate fortification. Neuroepidemiology (2005) 0.83
CT findings in acute myocarditis: 2 cases. J Thorac Imaging (2007) 0.83
Oxygen therapy in ischemic stroke. Stroke (2003) 0.82
Diagnostic potential of the NMDA receptor peptide assay for acute ischemic stroke. PLoS One (2012) 0.82
Arterial vimentin is a transglutaminase substrate: a link between vasomotor activity and remodeling? J Vasc Res (2007) 0.81
Role of anti-PF4/heparin antibodies in recurrent thrombotic events after acute coronary syndromes. Semin Thromb Hemost (2004) 0.80
Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis. FASEB J (2003) 0.80
Zebrafish with antisense-knockdown of cardiac troponin C as a model of hereditary dilated cardiomyopathy. Circ J (2009) 0.79
Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Eur J Pharmacol (2004) 0.79
Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes. J Thromb Thrombolysis (2004) 0.79
Weekly doxorubicin increases coronary arteriolar wall and adventitial thickness. PLoS One (2013) 0.79
Derived fibrinogen compared with C-reactive protein and brain natriuretic peptide for predicting events after myocardial infarction and coronary stenting. Am Heart J (2008) 0.78
The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J (2002) 0.78
Unfractionated heparin reduces the anti-platelet effects of abciximab but not eptifibatide during PCI. Clin Appl Thromb Hemost (2006) 0.78
Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. Thromb Res (2004) 0.78
Differences in baseline characteristics and in-hospital outcomes in patients with or without prior stroke undergoing percutaneous coronary intervention. J Invasive Cardiol (2005) 0.78
Development, validation, and application of a microsimulation model to predict stroke and mortality in medically managed asymptomatic patients with significant carotid artery stenosis. Value Health (2007) 0.77
Bicuspid aortic valves in monozygotic twins. Echocardiography (2003) 0.77
Calcification after myocardial infarction is independent of amniotic fluid stem cell injection. Cardiovasc Pathol (2010) 0.77
Screening for high-grade carotid stenosis using a portable ultrasonography instrument. J Neuroimaging (2006) 0.77
The changing risk factor profile of participants enrolled in a secondary stroke prevention trial: Vitamin intervention for stroke prevention. Neuroepidemiology (2006) 0.77
Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? Am Heart J (2003) 0.76
No effect of an L-arginine-enriched medical food (HeartBars) on endothelial function and platelet aggregation in subjects with hypercholesterolemia. Am Heart J (2003) 0.76
Preprocedural white blood cell count and major adverse cardiac events late after percutaneous coronary intervention in saphenous vein grafts. Am J Cardiol (2005) 0.76
Stroke rehabilitation. Continuum (Minneap Minn) (2011) 0.76
C-Terminally fused affinity Strep-tag II is removed by proteolysis from recombinant human erythropoietin expressed in transgenic tobacco plants. Plant Cell Rep (2014) 0.75
Letter by Sane regarding article, "New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United kingdom and Ireland". Circulation (2008) 0.75
Validation of homocyst(e)ine-lowering treatment in the era of folic acid fortification of cereal grains. Arterioscler Thromb Vasc Biol (2002) 0.75
Food (and vitamins) for thought. Neurology (2002) 0.75
Optimal TARGETs for cardiovascular safety and benefit in ESRD. Nephrol Dial Transplant (2008) 0.75
Telomerase-positive neutrophils: plaque "survivors" and restenosis. J Am Coll Cardiol (2008) 0.75
Link between ADAMTS-13 and troponin levels? Crit Care Med (2008) 0.75
Cardiac manifestations of cutaneous disorders. J Am Acad Dermatol (2012) 0.75
Interference of thrombin in immunological assays for hirudin specific antibodies. J Immunol Methods (2012) 0.75
Direct thrombin inhibitors in the treatment of immune-mediated heparin-induced thrombocytopenia. Semin Thromb Hemost (2004) 0.75
Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions. J Invasive Cardiol (2004) 0.75
Multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation (DESIR-ABLE). Clin Appl Thromb Hemost (2012) 0.75
Neural networks for ischemic stroke. J Stroke Cerebrovasc Dis (2007) 0.75
Multimer formation by FKBP-12: roles for cysteine 23 and phenylalanine 36. J Pept Sci (2007) 0.75
Rapid platelet inhibition after a single capsule of Aggrenox: challenging a conventional full-dose aspirin antiplatelet advantage? Am J Hematol (2003) 0.75
Persistent erythema with niacin is not attributable to aspirin resistance. J Clin Lipidol (2011) 0.75
Case studies of HIT in cardiovascular medicine. Semin Thromb Hemost (2004) 0.75
Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits. J Cardiovasc Pharmacol (2004) 0.75
Safety of abciximab administration during PCI of patients with previous stroke. J Thromb Thrombolysis (2005) 0.75
PCI with and without abciximab after upstream eptifibatide use: outcomes in high-risk patients. J Invasive Cardiol (2006) 0.75
Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity? Blood Coagul Fibrinolysis (2007) 0.75
Part 2: history of 20th century neurology: decade by decade. Ann Neurol (2003) 0.75
Correction: Diagnostic Potential of the NMDA Receptor Peptide Assay for Acute Ischemic Stroke. PLoS One (2013) 0.75